BACKGROUND AND OBJECTIVE: The dual orexin receptor antagonist daridorexant was approved in 2022 for the treatment of insomnia at doses up to 50 mg once per night. This study aimed at investigating the effect of daridorexant 50 mg at steady state on the pharmacokinetics of dabigatran, the active moiety of dabigatran etexilate, and rosuvastatin, sensitive substrates of P-glycoprotein and breast cancer resistance protein, respectively. METHODS: This single-center, open-label, fixed-sequence study enrolled 24 healthy male subjects who were dosed orally with dabigatran etexilate 75 mg on days 1 (Treatment A1) and 9 (Treatment C1) as well as rosuvastatin 10 mg on days 3 (Treatment A2) and 11 (Treatment C2). On days 7-14, daridorexant (50 mg once daily) was administered. Blood samples for the pharmacokinetics of both substrates and the pharmacodynamics of dabigatran, i.e., two coagulation tests, were collected and safety assessments performed. Noncompartmental pharmacokinetic parameters and pharmacodynamic variables were evaluated with geometric mean ratios and 90% confidence intervals of Treatment C1/C2 versus A1/A2. RESULTS: Geometric mean ratios (90% confidence interval) of dabigatran maximum plasma concentration and area under the plasma concentration-time curve were 1.3 (1.0-1.7) and 1.4 (1.1-1.9), respectively, whereas the time to maximum plasma concentration and terminal half-life were comparable between treatments. Pharmacodynamic variables showed a similar pattern as dabigatran pharmacokinetics in both treatments. Rosuvastatin pharmacokinetics were unchanged upon concomitant daridorexant administration. All treatments were well tolerated. CONCLUSIONS: A mild inhibition of P-glycoprotein was observed after administration of daridorexant (50 mg once daily) at steady state, whereas breast cancer resistance protein was not affected. CLINICAL TRIAL REGISTRATION: NCT05480475; date of registration: 29 July, 2022.

CEPHA s r o Pilsen Czech Republic

Department of Clinical Pharmacology Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91 4123 Allschwil Switzerland

Zobrazit více v PubMed

Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21:125–39. PubMed DOI

US Food and Drug Administration. Quviviq (daridorexant): highlights of prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf . Accessed 1 Mar 2023.

European Medicines Agency. Quviviq (daridorexant) summary of product characteristics. EU/1/22/1638/001. 2022. https://www.ema.europa.eu/en/documents/product-information/quviviq-epar-product-information_en.pdf . Accessed 1 Mar 2023.

Muehlan C, Heuberger J, Juif P-E, Croft M, van Gerven J, Dingemanse J. Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study. Clin Pharmacol Ther. 2018;104:1022–9. PubMed DOI

Muehlan C, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration. Eur Neuropsychopharmacol. 2019;29:847–57. PubMed DOI

Fietze I, Bassetti CLA, Mayleben DW, Pain S, Seboek Kinter D, McCall WV. Efficacy and safety of daridorexant in older and younger adults with insomnia disorder: a secondary analysis of a randomised placebo-controlled trial. Drugs Aging. 2022;39:795–810. PubMed DOI PMC

Zammit G, Dauvilliers Y, Pain S, Sebök Kinter D, Mansour Y, Kunz D. Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology. 2020;94:e2222–32. PubMed DOI

Muehlan C, Boehler M, Brooks S, Zuiker R, van Gerven J, Dingemanse J. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. J Psychopharmacol. 2020;34:326–35. PubMed DOI

Kunz D, Dauvilliers Y, Benes H, García-Borreguero D, Plazzi G, Seboek Kinter D, et al. Long-term safety and tolerability of daridorexant in patients with insomnia disorder. CNS Drugs. 2023;37:93–106. DOI

Muehlan C, Fischer H, Zimmer D, Aissaoui H, Grimont J, Boss C, et al. Metabolism of the dual orexin receptor antagonist ACT-541468, based on microtracer/accelerator mass spectrometry. Curr Drug Metab. 2019;20:254–65. PubMed DOI

European Medicines Agency. Assessment report: Quviviq (daridorexant). Committee for Medicinal Products for Human Use (CHMP). 2022. https://www.ema.europa.eu/en/documents/assessment-report/quviviq-epar-public-assessment-report_en.pdf . Accessed 1 Mar 2023.

Zenklusen I, Muehlan C, Ulc I, Liška J, Dingemanse J. The dual orexin receptor antagonist daridorexant does not affect the pharmacokinetics of the BCRP substrate rosuvastatin. Clin Exp Pharmacol Physiol. 2020;47:1843–9. PubMed DOI

Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport: an update. AAPS J. 2015;17:65–82. PubMed DOI

Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215–36. PubMed DOI

Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2014;14:29–44. PubMed DOI PMC

US Food and Drug Administration. Clinical drug interaction studies: cytochrome P450 enzyme- and drug interactions guidance for industry. Center for Drug Evaluation and Research (CDER). 2020. p. 1–27. https://www.fda.gov/media/134581/download . Accessed 18 Oct 2022.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline: drug interaction studies (M12). 2022. p. 1–69. https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf . Accessed 18 Oct 2022.

European Medicines Agency. Guideline on the investigation of drug interactions. CPMP/EWP/560/95/Rev. 1 Corr. 2 Committee for Medicinal Products for Human Use (CHMP) guideline; 2012: p. 59.

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303. PubMed DOI PMC

Chu X, Galetin A, Zamek-Gliszczynski MJ, Zhang L, Tweedie DJ. Dabigatran etexilate and digoxin: comparison as clinical probe substrates for evaluation of P-gp inhibition. Clin Pharmacol Ther. 2018;104:788–92. PubMed DOI

US Food and Drug Administration. Pradaxa highlights of prescribing Information. 2010: p. 1–25. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf . Accessed 12 Apr 2023.

European Medicines Agency. Pradaxa (dabigatran etexilate) summary of product characteristics. EU/1/08/442/002. 2018. https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_en.pdf . Accessed 28 Feb 2023.

Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2006;20:303–28. DOI

Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015;71:329–40. PubMed DOI

Berger B, Muehlan C, Klein G, Dingemanse J. Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment. Clin Transl Sci. 2021;14:2132–8. PubMed DOI PMC

Dubé C, Douketis JD, Moffat KA, Schulman S, Blais N. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: analysis of five activated partial thromboplastin time reagents and thrombin time. Thromb Res. 2018;171:62–7. DOI

EMA. Crestor (Rosuvastatin) amended summary of product characteristics. 2005. p. 1–11. https://www.ema.europa.eu/en/documents/referral/crestor-5-mg-article-29-referral-annex-i-ii-iii_en.pdf . Accessed 1 Mar 2023.

Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006;62:527–37. DOI PMC

Milos M, Herak D, Kuric L, Horvat I, Zadro R. Evaluation and performance characteristics of the coagulation system: ACL TOP analyzer—HemosIL reagents. Int J Lab Hematol. 2009;31:26–35. PubMed DOI

Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74:490–500. PubMed DOI PMC

Martin P, Gillen M, Ritter J, Mathews D, Brealey C, Surry D, et al. Effects of fostamatinib on the pharmacokinetics of oral contraceptive, warfarin, and the statins rosuvastatin and simvastatin: results from phase I clinical studies. Drugs R D. 2016;16:93–107. PubMed DOI PMC

Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, et al. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2017;101:519–30. PubMed DOI

Tatosian DA, Yee KL, Zhang Z, Mostoller K, Paul E, Sutradhar S, et al. A microdose cocktail to evaluate drug interactions in patients with renal impairment. Clin Pharmacol Ther. 2021;109:403–15. PubMed DOI

Rattanacheeworn P, Kerr SJ, Kittanamongkolchai W, Townamchai N, Udomkarnjananun S, Praditpornsilpa K, et al. Quantification of CYP3A and drug transporters activity in healthy young, healthy elderly and chronic kidney disease elderly patients by a microdose cocktail approach. Front Pharmacol. 2021;12:1–14. DOI

Deng F, Sjöstedt N, Santo M, Neuvonen M, Niemi M, Kidron H. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs. Eur J Pharm Sci. 2023;181: 106362. PubMed DOI

Deng F, Tuomi S-K, Neuvonen M, Hirvensalo P, Kulju S, Wenzel C, et al. Comparative hepatic and intestinal efflux transport of statins. Drug Metabol Dispos. 2021;49:750–9. DOI

Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, et al. Cytochrome P450 3A induction predicts P-glycoprotein induction; part 1: establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther. 2018;104:1182–90. PubMed DOI PMC

Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, et al. Cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther. 2018;104:1191–8. PubMed DOI PMC

Boof ML, Dingemanse J, Brunke M, Esselmann A, Heymer P, Kestermann O, et al. Effect of the novel dual orexin receptor antagonist daridorexant on night-time respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease. J Sleep Res. 2021;30:1–10. DOI

Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother. 2017;61:1–12. DOI

Monk SA, Kugler AR, Andersen SW, Ayan-Oshodi MA, James DE, Mullen J, et al. Clinically negligible pharmacokinetic and pharmacodynamic interactions between lanabecestat and dabigatran etexilate, a prototypical P-gp substrate. J Clin Pharmacol. 2020;60:586–94. PubMed DOI

Dimatteo C, D’Andrea G, Vecchione G, Paoletti O, Cappucci F, Tiscia GL, et al. Pharmacogenetics of dabigatran etexilate interindividual variability. Thromb Res. 2016;144:1–5. PubMed DOI

Bhatt DK, Mehrotra A, Gaedigk A, Chapa R, Basit A, Zhang H, et al. Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. Clin Pharmacol Ther. 2019;105:131–41. PubMed DOI

Božič-Mijovski M, Malmström RE, Malovrh P, Antovic JP, Vene N, Šinigoj P, et al. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations. Ann Clin Biochem. 2016;53:446–51. PubMed DOI

Avecilla ST, Ferrell C, Chandler WL, Reyes M. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol. 2012;137:572–4. PubMed DOI

Ericsson H, Nelander K, Heijer M, Kjaer M, Lindstedt EL, Albayaty M, et al. Phase 1 pharmacokinetic study of AZD5718 in healthy volunteers: effects of coadministration with rosuvastatin, formulation and food on oral bioavailability. Clin Pharmacol Drug Dev. 2020;9:411–21. DOI

Katsube T, Miyazaki S, Narukawa Y, Hernandez-Illas M, Wajima T. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol. 2018;74:931–8. PubMed DOI

Ou YC, Tang Z, Novotny W, Tawashi M, Li TK, Coleman HA, et al. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP. Br J Clin Pharmacol. 2021;87:2926–36. DOI

Muehlan C, Zuiker R, Peeters P, Rowles R, Dingemanse J. Pharmacokinetics and pharmacodynamics of the dual orexin receptor antagonist daridorexant in Japanese and Caucasian subjects. J Clin Psychopharmacol. 2020;40:157–66. PubMed DOI

Vourvahis M, Byon W, Chang C, Le V, Diehl A, Graham D, et al. Evaluation of the effect of abrocitinib on drug transporters by integrated use of probe drugs and endogenous biomarkers. Clin Pharmacol Ther. 2022;112:665–75. PubMed DOI PMC

Oswald S. Drug transporters in the human intestine. In: You G, Morris ME, editors. Drug transporters. New York: Wiley; 2022. p. 333–59. DOI

Krause A, Lott D, Brussee JM, Muehlan C, Dingemanse J. Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist. CPT Pharmacometr Syst Pharmacol. 2023;12:74–86. DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05480475